Form 8-K VALUE LINE INC For: Jan 16

false 0000717720 0000717720 2026-01-16 2026-01-16

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

 

 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of the earliest event reported): January 16, 2026

 

(Exact name of registrant as specified in its charter)

 

 

551 Fifth Avenue
New York, New York
(Address of Principal Executive Offices)

(Zip Code)

 

(212) 907-1500
(Registrant’s Telephone Number, Including Area Code)

 

(Former Name or Former Address, if Changed Since Last Report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the of the Securities Exchange Act of 1934.

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Mr. Alfred R. Fiore, a director of the Company since 2010, died on December 6, 2025.

 

On January 16, 2026, Dr. Alexander J. Swistel was appointed by the Board of Directors of Value Line, Inc. (the “Company”) to serve as director of the Company and as a member of the Board’s Audit Committee. Dr. Swistel is retired Associate Professor at Weill Cornell Medical College and is a graduate of Harvard University and Brown University School of Medicine. There is no arrangement or understanding between Dr. Swistel and any other person pursuant to which Dr. Swistel was selected as a director of the Company. No family relationships exist between Dr. Swistel and any of the Company’s directors or executive officers. There are no transactions to which the Company was or is a participant and in which Dr. Swistel has a material interest subject to disclosure under Item 404(a) of Regulation S-K. Dr. Swistel will receive the same compensation as other members of the Audit Committee, which is a director’s fee of $40,000 per year.

 

 

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Date: January 16, 2026